Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
– Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne – Study endpoints include safety and tolerability, effect on muscle force and function, and impact on muscle quality and regeneration
(Financial Post, 2025-12-09T12:05:06Z)